Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
1(50.0%)
N/A
1(50.0%)
2Total
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06226857Phase 3Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Role: collaborator

NCT04119596Terminated

Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease

Role: lead

NCT04113239Completed

Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus

Role: lead

NCT04114513Not ApplicableWithdrawn

Dietary Fibers Effect on the Gut Microbiota Composition

Role: lead

All 4 trials loaded